Crossmark

Vision-related quality of life in Japanese patients with wet age-related macular degeneration treated with intravitreal aflibercept in a real-world setting

Crossref DOI link: https://doi.org/10.1007/s10384-019-00687-2

Published Online: 2019-10-31

Published Print: 2019-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Gomi, Fumi

Migita, Hideyuki

Sakaguchi, Toshiaki

Okada, Hiromi

Sugawara, Tamotsu

Hikichi, Yusuke https://orcid.org/0000-0002-1699-6821
License Information

Text and Data Mining valid from 2019-10-31

Version of Record valid from 2019-10-31
More Information

Article History

Received: 22 August 2018

Accepted: 16 July 2019

First Online: 31 October 2019

Conflicts of interest

: F. Gomi, Honorarium (Bayer, Alcon, Novartis, Santen, Senju), Speaker fee (Alcon, Bayer, Santen, Senju), Advisory board fee (Alcon, Bayer, Senju), Grant (Alcon, Bayer, Johnson and Johnson, Nidek, Novartis, Pfizer, Santen, Senju), H. Migita, Employee (Bayer); T. Sakaguchi, Employee (Bayer); H. Okada, Consultant fee (Bayer); T. Sugawara, Consultant fee (Bayer); Y. Hikichi, Employee (Bayer).

Document is current

Any future updates will be listed below